CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Autor: C Chouaid, N Girard, A Kron, M Scheffler, C Knott, L Bosquet, J Trigo, S Viteri, M Sebastian, S Popat, N Rahhali, R Toueg, B Rodrigues, J Diels, CA Schioppa, J Cabrieto, J Sermon, NJ Perualila, N Erdmann, J Mielke, M Nematian-Samani, I Pfaira, C Martin-Fernandez, P Mahadevia, T Li, C Pick-Lauer, A Adamczyk, J Penton, J Wolf

Publikováno v: Value in Health. 25:S32

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b96eebb8bd08ca951e7758986743303e
https://doi.org/10.1016/j.jval.2022.09.152

A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study.

Autor: Girard N; Institut Curie, Institut du Thorax Curie-Montsouris, 42 Bd Jourdan, Paris 75014, France. Electronic address: nicolas.girard2@curie.fr., Park K; Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, the Republic of Korea., Lee SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, the Republic of Korea., Viteri S; Instituto Oncológico Dr Rosell, Hospital Universitario Dexeus, Grupo Quirónsalud, Carrer de Sabino Arana, 5, Barcelona 08028, Spain., Schioppa CA; Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse B-2340, Belgium., Diels J; Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse B-2340, Belgium., Oguz M; Janssen-Cilag, 50-100 Holmers Farm Way, High Wycombe HP12 4EG, United Kingdom., Rodrigues BH; Janssen-Cilag, Lagoas Park, Edifício 9, Porto Salvo 2740-262, Portugal., Rahhali N; Janssen-Cilag, 1 rue Camille Desmoulins, Issy-les-Moulineaux 92130, France., Sermon J; Janssen-Cilag NV, Turnhoutseweg 30, Beerse B-2340, Belgium., Ghilotti F; Janssen-Cilag SpA, Via Michelangelo Buonarroti, 23, Cologno Monzese 20093, Italy., Li T; Janssen Research & Development, 1000 U.S. Route 202 South, Raritan, NJ 08869, United States., Thayu M; Janssen Research & Development, 1400 McKean Rd, Spring House, PA 19002, United States., Knoblauch RE; Janssen Research & Development, 1400 McKean Rd, Spring House, PA 19002, United States., Mahadevia P; Janssen Research & Development, 1000 U.S. Route 202 South, Raritan, NJ 08869, United States., Cho BC; Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, the Republic of Korea.

Publikováno v: Cancer treatment and research communications [Cancer Treat Res Commun] 2024; Vol. 40, pp. 100832. Date of Electronic Publication: 2024 Jul 09.

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.

Autor: Chouaid C; Service de Pneumologie, Pneumology, Intercommunal Hospital, 40 avenue de Verdun, 94010, Créteil, France. christos.chouaid@chicreteil.fr., Bosquet L; Health Data and Partnerships Department, Unicancer, Paris, France., Girard N; Institut Curie, Paris, France., Kron A; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.; Network Genomic Medicine, Cologne, Germany.; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Scheffler M; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.; Network Genomic Medicine, Cologne, Germany.; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Griesinger F; Department of Hematology and Oncology, University Department Internal Medicine-Oncology, Pius-Hospital, University Medicine Oldenburg, Oldenburg, Germany., Sebastian M; Department of Medicine, Hematology and Oncology, University of Frankfurt, Frankfurt, Germany., Trigo J; Hospital Universitario Virgen de la Victoria y Regional, IBIMA, Malaga, Spain., Viteri S; UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, Spain.; Instituto Oncológico Dr Rosell, Hospital Universitari Dexeus, Grupo QuironSalud, Barcelona, Spain., Knott C; Health Data Insight CIC, Cambridge, UK.; National Disease Registration Service, NHS Digital, Leeds, UK., Rodrigues B; Janssen Cilag, Porto Salvo, Portugal., Rahhali N; Janssen Cilag, Île-de-France, France., Cabrieto J; Janssen Pharmaceutica NV, Beerse, Belgium., Diels J; Janssen Pharmaceutica NV, Beerse, Belgium., Perualila NJ; Janssen Pharmaceutica NV, Beerse, Belgium., Schioppa CA; Janssen Pharmaceutica NV, Beerse, Belgium., Sermon J; Janssen Pharmaceutica NV, Beerse, Belgium., Toueg R; Janssen Cilag, Île-de-France, France., Erdmann N; Janssen-Cilag GmbH, Neuss, Germany., Mielke J; Janssen-Cilag GmbH, Neuss, Germany., Nematian-Samani M; Janssen-Cilag GmbH, Neuss, Germany., Martin-Fernandez C; Janssen-Cilag Ltd, High Wycombe, UK., Pfaira I; Janssen-Cilag Ltd, High Wycombe, UK., Li T; Janssen R&D, Raritan, NJ, USA., Mahadevia P; Janssen R&D, Raritan, NJ, USA., Wolf J; Lung Cancer Group Cologne, Department I for Internal Medicine and Center for Integrated Oncology Cologne/Bonn, University Hospital Cologne, Cologne, Germany.; Network Genomic Medicine, Cologne, Germany.

Publikováno v: Advances in therapy [Adv Ther] 2023 Mar; Vol. 40 (3), pp. 1187-1203. Date of Electronic Publication: 2023 Jan 18.